QR non - recurrent - ISPF ODA Funds
2024 - 225
| Recognition Type | Internal funding award |
|---|---|
| Description | The substantial morbidity and mortality burden attributed to Malaria is primarily borne (90%) by sub-Saharan Africa with 700,000 deaths and 3 million infections annually. Drug resistance reported in ALL currently used drugs threatens to cause a catastrophic void in the drug market. Resistance to the current first line drug Artemisinin was first reported in the Greater Mekong Subregion (GMS) in 2007 and has now, predictably, spread to North India and East Africa with significant implications for effective control of this diseases (Zhou et al, 2022). Recent African foci for the PfK13-propeller domain marker mutation have emerged in Rwanda, Ethiopia and Ghana. In Kenya, one of the endemic countries, antimalarial treatment failures have been reported as evidence of artemisinin resistance as early as 2015 (Osborne et al., 2023). Despite dedicated effects to control the disease, the Lake Victoria (Kisumu, Kenya) region and the coastal regions of the country still face a heavy disease burden. The need to find alternative affordable substitutes for drug resistance is therefore, an urgent priority |
| Research Centres/Groups | Biomedical Research |
| Org Units | School of Science, Engineering & Environment |